USA patent/origin
- Finger prick specimen allows testing at point-of-care, saving crucial time
- Results within15 minutes allow doctors to take immediate action 97.1% Sensitivity, 97.8% Specificity (vs. PCR-confirmed specimens)
-  Complementary to PCR by detecting immune response
- Compatible with CTK Rapid Test Reader (RTR-1)
Evaluation of 9 commercial SARS-CoV-2 immunoassays
Absorbent pad
Analytical pad
Conjugate pad 
Sample pad
COVID-19 is a new illness that can affect your lungs & airways. It's caused by a virus called coronavirus.
OnSite COVID-19 IgG/IgM Rapid Test
INTERNATIONAL ARMOUR STRATEGIC BUSSINES PARTNER
(*) REQUESTED PRODUCTS & QUANTITIES
RFQ FORM
Requests with incomplete information will not be considered as true and valid
(*) Ultimate Country of Destination:

Shipping method:

(*) RFQ is for Direct order or Tender
What is 5+2?
(Prove that you are Human)
(*) Mandatory fields
Sender declares that his Company is not listed in/or associated with any other Company or individual in the Consolidated United Nations Security Council Sanctions List.
(*) Company Firm/Name:
(*) Registered Country:
Company’s Website (URL):
(*) Email:
(*) Contact person:
(*) Cellular phone(s):
Contact person WhatsApp:
Copyright Fenix Global Company Ltd, All rights reserved
We only legal trade with countries/companies that are not under any sanction by the UN and the EU
516600
011DU
 
OnSite COVID-19 IgG/IgM Rapid Test
The OnSite COVID-19 IgG/IgM Rapid Test is designed for initial screening by detecting anti-SARS-CoV-2 IgG and IgM antibodies in either human serum, plasma or whole blood within 15 minutes.

This test is easy-to-use, requires only minimally skilled personnel with basic equipment needs

The OnSite COVID-19 IgG/IgM Rapid Test has 97.1% sensitivity and 97.8% specificity making it one of the most effective screening tests for COVID-19.
97.1% Sensitivity
97.8% Specificity